Treatment of nonproliferative diabetic retinopathy with Defibrotide in noninsulin-dependent diabetes mellitus: A pilot study

Acta Ophthalmologica Scandinavica

Volumn 77, Issue 3, 1999, Pages 315-320

  Vingolo, Enzo Maria ^a   De Mattia, Giancarlo ^a   Giusti, Cristiano ^a,b   Forte, Renato ^a   Laurenti, Oriana ^a   Pannarale, Mario Rosario ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b NONE   (Italy)

Author keywords

Defibrotide; Diabetic retinopathy; Noninsulin dependent diabetes mellitus; Retina

Indexed keywords

DEFIBROTIDE; ENDOTHELIN 1; FLUORESCEIN; PROSTACYCLIN;

ADULT; AGED; ARTICLE; BLOOD CLOTTING; CELL PROTECTION; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED PERIMETRY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC RETINOPATHY; DISEASE COURSE; FEMALE; FIBRINOLYSIS; FLUORESCENCE ANGIOGRAPHY; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PILOT STUDY; PRIORITY JOURNAL; RETINOGRAPHY; STATISTICAL ANALYSIS; VASCULAR ENDOTHELIUM; VISUAL ACUITY;

EID: 0033009504     PISSN: 13953907     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0420.1999.770314.x     Document Type: Article

References (29)

1. Abbate R, Gori AM, Martini F, Attanasio M, Comeglio P, Giusti B, Zarone N. Francalanci I, Frisco D, Gensini GF (1995): Defibrotide reduces monocyte PAI-2 and procoagulant activity. Seminars in Thrombosis and Haemostasis 21: 245-250.
2. Almèr L-O, Pandolfi M, Nilsson IM (1975): Diabetic retinopathy and the fibrinolytic system. Diabetes 24: 529-534.
3. Berti F, Rossoni G, Ferro L, Trento F, Villa LM, Pompilio G, Sala A (1994): Defibrotide, via prostacycline release, antagonizes endothelin-1 induced vasospasm in rabbit and human coronary artery. Internal Medicine 2: 49-56.
4. Cappelli R, Pecchi S, Pieragalli D, Acciavatti A. Galicani C, Messa GL, Vittoria A, Guerrini M, Forconi S, Di Perri T (1987): Effect on rheological and some peripheral haemodinamic parameters of Defibrotide in PAOD patients. Clinical Hemorheology 7: 247-252.
5. Diabetic Retinopathy Study Research Group: Report 7 (1981): A modification of the Airlie House Classification of Diabetic Retinopathy. Invest Ophthalmol Vis Sci 21: 210-226.
6. Egeberg O (1963): The blood coagulability in diabetic patients. Scand J Clin Lab Invest 15: 533-538.
7. Fareed J, Lindel G, Walenga JM (1990): Pharmacologic validation of the antithrombotic and vascular effects of Defibrotide. In: Strano A, Novo S (eds). Advances in vascular pathology, p 171-177. Elsevier Science Publishers.
8. De Mattia G, Vingolo EM, Laurenti O, Cassone Faldetta M, Barcaroli M, Giusti C, Zicari D, Ferri C (1996): Plasma endothelin-1 (ET-1) levels as marker of retinopathy in NIDDM patients. Proceedings ARVO 1996 - Fort Lauderdale (FL - USA) April 21-26, 1996. Invest Ophthalmol Vis Sci 37: S958.
9. Garcìa Frade LJ, de la Calle H, Torado MC, Lara JL, Cuellar L, Garcìa Avello A (1990): Hypofibrinolysis associated with vasculopathy in non-insulin-dependent diabetes mellitus. Thromb Res 59: 51-59.
10. Gargiulo P, Ciampalini D, Bosco D, Schiaffini R, Pantaleo A, Arcieri P, Vingolo EM (1995): Procoagulant activity and diabetic retinopathy in a selected group of type 1 diabetic patients. Proceedings EASD - 31st Annual Meeting of the European Association for the Study of Diabetes. Stockholm (Sweden) September 12-16, 1995. Diabetologia 38 (Suppl 1): A257.
11. Gargiulo P, Pantaleo A, Arcieri P, Mariani G (1994): Possibile utilizzo del Defibrotide nella prevenzione delle complicanze vascolari del diabete mellito. Proceedings SID '94-XV○ Congresso Nazionale della Società Italiana di Diabetologia. Il Diabete 6 (Suppl 1): 79.
12. Heath H, Brigden WD, Canever JV, Pollock J, Hunter PR, Kelsey J, Bloom A (1971): Platelet adhesiveness and aggregation in relation to diabetic retinopathy. Diabetologia 7: 308-315.
13. Klein R, Klein BEK, Moss SE, Davis MD, De-Mets DL (1987): The Wisconsin Epidemiologic Study of Diabetic Retinopathy. VII. Diabetic nonproliferative retinal lesions. Ophthalmology 94: 1389-1400.
14. Klein BEK, Klein R, Moss SE, Davis MD, De-Mets DL (1989): The Wisconsin Epidemiologic Study of Diabetic Retinopathy. X. Four year incidence and progression of diabetic retinopathy when age at diagnosis is 30 years of age or older. Arch Ophthalmol 107: 244-249.
15. Klein R, Klein BEK, Moss SE, Cruickshanks KJ (1994): The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XIV Ten year incidence and progression of diabetic retinopathy. Arch Ophthalmol 112: 1217-1228.
16. Kumar A, Fareed J, Wehrmacher WH, Hoppensteadt D, Ulutin O, Walenga JM (1987): Endothelial function modulation and control of vascular and thrombotic disorders: experimental results with a polydeoxyribonucleotide agent Defibrotide. Proceedings XIth International Congress on Thrombosis and Haemostasis. Bruxelles (Belgium) July 6-10, 1987. Thromb Haemost 58: 100.
17. Moeei R, Chiurazzi D, Germiniani R, Pacini F (1986): Effectiveness of Defibrotide for prophylaxis of deep venous thrombosis after general surgery: a double-blind placebo-controlled clinical trial. Haemostasis 16 (Suppl): 36-38.
18. Mussoni L, Evolvi C, Donati MB (1979): Activation of plasma and vascular fibrinolytic activity by a polideoxyribonuclotidic substance (fraction P) in rats and rabbits. Proceedings VIIth International Congress on Thrombosis and Haemostasis. London (England) July 15-20, 1979. Thromb Haemost 42: 388.
19. O' Brien JR, Etheringten MD, Pasheley M, Jeffries J (1984): The effects in human of Defibrotide i.v. on numerous blood parameters. Haemostasis 14: A227.
20. Pandolfi M, Almèr L-O, Holmberg L (1974): Increased von Willebrand-antihaemophilic factor A in diabetic retinopathy. Acta Ophthalmologica 52: 823-828.
21. Pola P, Tondi P, Favuzzi A, De Martini D, Gerardino L, Fiormonte F, Marchi V (1993): Treatment of retinal vein thrombosis with Defibrotide. Current Therapeutic Research 53 (3): 340-346.
22. Schiaffini R, Ciampalini P, Bosco D, Romani B, Vaccari V, Arcieri P, Gargiulo P (1995): Lupus Anticoagulant dependent thrombotic tendency in type 1 Diabetes mellitus. Proceedings EASD - 31st Annual Meeting of the European Association for the Study of Diabetes. Stockholm (Sweden) September 12-16, 1995. Diabetologia 38 (Suppl 1): A257.
23. Schror K, Ackerman G, Schroder N, Ney P, Lobel P, Hohlfeld T (1989): Stimulation of endogenous prostacyclin by Defibrotide. Mechanisms and their possible significance for platelet function. Proceedings III Erfurt Workshop on platelets. Erfurt (Germany) June 26-30, 1989. Abstract Book p 43.
24. Trick GL, Trick LR, Kilo C (1990): Visual field defects in patients with insulin-dependent and noninsulin-dependent diabetes. Ophthalmology 97: 475-482.
25. Ulutin ON, Ilhan N, Tunali H (1986): Effects of Defibrotide on peripheral obliterative vascular disease. Haemostasis 16 (Suppl): 59-62.
26. Ulutin ON (1988): Clinical effectiveness of Defibrotide in vaso-occlusive disorders and its mode of actions. Seminars in Thrombosis and Hemostasis 14 (Suppl): 58-83.
27. Vingolo EM, Pannarale L, Forte R, Bruni P, Zicari D (1994): Il trattamento delle occlusioni dell'arteria centrale della retina con Defibrotide. Studio preliminare. Boll Ocul 5: 3-12.
28. Violi F, Ferro D, Alessandri C, Quintarelli C, Saliola M. Balsano F (1989): Inhibition of tissue plasminogen activator inhibitor by Defibrotide in atherosclerotic patients. Seminars in Thrombosis and Haemostasis 15: 226-229.
29. Zhou Q, Chu X, Ruan C (1994): Defibrotide stimulates expression of thrombomodulin in human endothelial cells. Thromb Haemost 71: 507-510.